Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$2.47 +8.3%	$1.53	$1.09 ▼ $7.67	$28.04M	0.63	3.73 million shs	86,504 shs
CLRB Cellectar Biosciences	$4.49 +1.8%	$5.94	$4.11 ▼ $68.70	$7.98M	0.42	156,538 shs	90,700 shs
MAAQ Mana Capital Acquisition	$3.50 -4.6%	$3.93	$5.35 ▼ $10.25	$28.44M	N/A	33,075 shs	29,645 shs
MURA Mural Oncology	$2.07 -1.0%	$2.27	$0.95 ▼ $4.74	$36.21M	3	489,667 shs	1.31 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	+8.33%	+27.32%	+96.81%	+32.09%	-62.00%
CLRB Cellectar Biosciences	+1.81%	+1.58%	-13.65%	-39.92%	-93.01%
MAAQ Mana Capital Acquisition	-4.63%	-6.42%	-18.60%	-17.45%	+677.95%
MURA Mural Oncology	-0.96%	+16.95%	-15.51%	-24.73%	-37.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	3.586 of 5 stars	3.5	3.0	0.0	4.3	0.0	1.7	0.0
CLRB Cellectar Biosciences	2.4307 of 5 stars	3.3	2.0	0.0	0.0	2.9	1.7	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	2.9618 of 5 stars	3.3	3.0	0.0	0.0	1.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	61.94% Upside
CLRB Cellectar Biosciences	2.50	Moderate Buy	$375.00	8,251.89% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
MURA Mural Oncology	2.50	Moderate Buy	$12.00	479.71% Upside

Current Analyst Ratings Breakdown

Latest CLRB, MURA, MAAQ, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	CLRB Cellectar Biosciences	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$28.54M	1.06	N/A	N/A	$0.12 per share	20.58
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$3.07 per share	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	$3.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/22/2025 (Estimated)
CLRB Cellectar Biosciences	-$44.58M	-$19.91	N/A	N/A	N/A	N/A	-486.67%	-150.57%	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	N/A

Latest CLRB, MURA, MAAQ, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/22/2025	N/A	CASI CASI Pharmaceuticals	-$0.47	N/A	N/A	N/A	$6.28 million	N/A
8/14/2025	Q2 2025	CLRB Cellectar Biosciences	-$3.60	-$3.39	+$0.21	-$3.39	N/A	N/A
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	N/A	0.81	0.68
CLRB Cellectar Biosciences	N/A	2.15	2.47
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
MURA Mural Oncology	N/A	2.87	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
CLRB Cellectar Biosciences	16.41%
MAAQ Mana Capital Acquisition	68.44%
MURA Mural Oncology	80.21%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
CLRB Cellectar Biosciences	5.04%
MAAQ Mana Capital Acquisition	N/A
MURA Mural Oncology	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable

CLRB, MURA, MAAQ, and CASI Headlines

Recent News About These Companies

Mural Oncology to be acquired by XRA 5 Corp. for $2.035-$2.24 per share in cash

August 20 at 7:18 PM | msn.com

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech

August 20 at 7:18 PM | finance.yahoo.com

MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders

August 20 at 10:40 AM | businesswire.com

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20 at 8:30 AM | globenewswire.com

Two new murals installed in Downtown Peoria

August 19 at 6:16 PM | msn.com

From courtyard to connection: KGH welcomes a new healing mural

August 19 at 6:16 PM | interiorhealth.caI

Why some in Columbia cared so much about saving Hunter-Gatherer’s bricks & mural

August 14, 2025 | thestate.comT

Mural Oncology (MURA) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Colourful mural celebrates 10 years of cancer care at WWL

August 4, 2025 | msn.com

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

August 4, 2025 | globenewswire.com

Artists help pupils and centre users create murals

August 3, 2025 | msn.com

Baltimore honors Henrietta Lacks with community-painted mural

August 2, 2025 | msn.com

Baltimore community comes together to complete Henrietta Lacks mural

August 2, 2025 | wmar2news.comW

Community news: Mural walk, health fair, digital skill lessons

July 28, 2025 | chicagotribune.com

Downtown Raleigh’s history unfolds in a sprawling new mural. Who is on it?

July 28, 2025 | msn.com

New mural inspires student growth on the Eastern Shore

July 28, 2025 | msn.com

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?

July 23, 2025 | finance.yahoo.com

Minneapolis muralist honors Tuskegee airmen

July 19, 2025 | msn.com

Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.de

July 8, 2025 | finanznachrichten.de

Demolition threatens breast cancer mural in 12 Points community

July 5, 2025 | wthitv.comW

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, MURA, MAAQ, and CASI Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$2.47 +0.19 (+8.33%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$2.46 -0.02 (-0.61%)

As of 08/21/2025 07:00 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Cellectar Biosciences NASDAQ:CLRB

$4.49 +0.08 (+1.81%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$4.48 -0.01 (-0.20%)

As of 08/21/2025 07:46 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Mana Capital Acquisition NASDAQ:MAAQ

$3.50 -0.17 (-4.63%)

As of 08/20/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Mural Oncology NASDAQ:MURA

$2.07 -0.02 (-0.96%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.01 (+0.24%)

As of 08/21/2025 07:08 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time